AsciepiX Therapeutics Inc. has announced the dosing of a Phase 1/2a clinical trial for diabetic macular edema (DME) using an intravitreal “self-forming gel depot peptide”.… Read More »AsciepiX Therapeutics Inc., (New Jersey, US) has announced the dosing of a Phase 1/2a trial of AXT107 for diabetic macular edema (DME).
Researchers based at the Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, CNRS, Paris, have reported partial recovery of visual function… Read More »A clinical study with a combined novel optogenetic therapy and a light-stimulating device has highlighted partial recovery of visual function on an RP patient.
Researchers based at the Institute of Ophthalmology, University College London, have identified a rare gene variant within RDH12, encoded by the retinal dehydrogenase enzyme functioning… Read More »A rare variant in RDH12 has been linked to autosomal dominant retinitis pigmentosa within a four-generation pedigree.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the June 1st, 2021 edition of EURETINA’s web-based digital magazine,… Read More »June 1st, 2021: “EURETINA-Brief”© Issue No. 236
MeiraGTx (Nasdaq: MGTX), has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its AAV-CNGA3 gene therapy for the treatment… Read More »MeiraGTx (NASDAQ: MGTX), a UK gene therapy company, has announced the receipt of Fast Track Designation by the FDA for the treatment of achromatopsia
Researchers at King’s College London, UK have reported that 192,986 European participants, across 10 populations, have identified 124 independent associations arising from 61 discrete genomic… Read More »A clinical study on eye colour, using genome-wide association analysis, has identified 50 previously unidentified genetic loci
Researchers based at Otto von Guericke University of Magdeburg and the Center of Behavioral Brain Sciences (CBBS), Germany, have reported results on siRNA treatment to… Read More »A novel apoptotic strategy has used siRNA to treat caspase-3 effectors protecting neuronal cells following optic nerve damage
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the May 18th, 2021 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »May 18th, 2021: “EURETINA-Brief”© Issue No. 235
Gemini Therapeutics (Nasdaq: GMTX), a US-based clinical stage ophthalmic company focused on age-related macular degeneration (AMD), has announced a Phase 2a treatment (“ReGAtta” study) and… Read More »Gemini Therapeutics (Cambridge, MA) expect to announce Phase 2a results in H12021 for dry AMD therapy.
Researchers at the Institute of Genetics, TCD, Dublin and the Department of Ophthalmology, McGill University, Montreal have reported significant research results supporting replenishment of the… Read More »Therapeutic implications reported in relation to a unique dominant RPE65 mutation with autosomal dominant retinitis pigmentosa (adRP)